DiaGenic ASA (NEL) - Product Pipeline Analysis, 2016 Update

Date: June 15, 2016
Pages: 28
Price:
US$ 750.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D692985AD87EN
Leaflet:

Download PDF Leaflet

DiaGenic ASA (NEL) - Product Pipeline Analysis, 2016 Update
Summary

DiaGenic ASA (DiaGenic) is a medical company that creates value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic products for early detection of diseases. The company specializes in developing blood-based biomarkers. Its ADtect product is a blood test that helps distinguish mild to moderate range AD from the absence of dementia. DiaGenic also has IP position, unique access to biobanks and mature technology in late stage development of products for commercialization in major markets. The company’s tests are based on the observation that a focal lesion or disorder gives rise to a systemic response which can be measured in the blood. DiaGenic is headquartered in Oslo, Norway.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company DiaGenic ASA
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
DiaGenic ASA Company Snapshot
DiaGenic ASA Company Overview
DiaGenic ASA Pipeline Products and Clinical Trials Overview
DiaGenic ASA – Pipeline Analysis Overview
Key Facts
DiaGenic ASA - Major Products and Services
DiaGenic ASA Pipeline Products by Development Stage
DiaGenic ASA Pipeline Products Overview
ADtect PLUS
ADtect PLUS Product Overview
ADtect ULTRA
ADtect ULTRA Product Overview
AMYtect
AMYtect Product Overview
MCItect - New Version
MCItect - New Version Product Overview
MCItect PLUS
MCItect PLUS Product Overview
MCItect ULTRA
MCItect ULTRA Product Overview
New ADtect
New ADtect Product Overview
PDtect
PDtect Product Overview
DiaGenic ASA - Key Competitors
DiaGenic ASA - Key Employees
DiaGenic ASA - Locations And Subsidiaries
Head Office
Recent Developments
DiaGenic ASA, Recent Developments
Aug 21, 2014: DiaGenic Announces Q2 2014 Financial Report
Mar 20, 2014: DiaGenic Appoints New CEO
Feb 20, 2014: DiaGenic: Report from Fourth Quarter 2013
Jan 31, 2014: DiaGenic: New CEO and New Company Address
Jan 23, 2014: DiaGenic reports AMYtect study results
Nov 22, 2013: Extraordinary General Meeting held in DiaGenic
Nov 22, 2013: Extraordinary general meeting held in DiaGenic ASA
Nov 13, 2013: DiaGenic ASA: Report from third quarter 2013
Nov 11, 2013: DiaGenic To Present results for third quarter 2013
Oct 29, 2013: DiaGenic provides update on AMYtect study
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

DiaGenic ASA Pipeline Products and Clinical Trials Overview
DiaGenic ASA Pipeline Products by Equipment Type
DiaGenic ASA Pipeline Products by Indication
DiaGenic ASA, Key Facts
DiaGenic ASA, Major Products and Services
DiaGenic ASA Number of Pipeline Products by Development Stage
DiaGenic ASA Pipeline Products Summary by Development Stage
ADtect PLUS - Product Status
ADtect PLUS - Product Description
ADtect ULTRA - Product Status
ADtect ULTRA - Product Description
AMYtect - Product Status
AMYtect - Product Description
MCItect - New Version - Product Status
MCItect - New Version - Product Description
MCItect PLUS - Product Status
MCItect PLUS - Product Description
MCItect ULTRA - Product Status
MCItect ULTRA - Product Description
New ADtect - Product Status
New ADtect - Product Description
PDtect - Product Status
PDtect - Product Description
DiaGenic ASA, Key Employees

LIST OF FIGURES

DiaGenic ASA Pipeline Products by Equipment Type
DiaGenic ASA Pipeline Products by Development Stage
Skip to top


Ask Your Question

DiaGenic ASA (NEL) - Product Pipeline Analysis, 2016 Update
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: